Strategic Performance and Market Dynamics
-
Net sales of XTENVI products grew more than 85% year-over-year, driven by a shift in physician behavior from treating only symptomatic conditions to universal screening of collarettes.
-
Management points to growth in the increasing depth of prescriptions, about half of the 15,000 intended eye care doctors now prescribe at least once a week.
-
The company is developing a ‘replicable playbook’ for identifying underdiagnosed diseases with clear roots, aiming to replicate XTENVI’s success in new therapeutic areas.
-
The growth of the market is fueled by the generation of evidence linking Demodex blepharitis to other conditions such as chalazion and hordeolum, which expands the clinical use of doctors.
-
Operational momentum is supported by a direct-to-consumer campaign that exceeds ROI benchmarks and drives a 40% quarter-over-quarter increase in high-value website engagement.
-
The strategic position is focused on establishing XTENVI as the permanent standard of care, even as potential competitors enter the Phase II clinical arena.
Growth Outlook and Strategic Plans
-
Full-year 2026 revenue guidance of $670 million to $700 million assumes seasonality in Q2, more modest growth in Q3, and stronger growth in Q4 as patients meet insurance deductibles.
-
The deployment of a new Key Account Leader team in the third quarter is expected to drive incremental growth by identifying potential trends to improve usage.
-
Management expects the sustainable return rate to reach around 20%, with current rates already trending upwards.
-
Peak data for the Phase II CALLIOPE study in the prevention of Lyme disease is expected in 2027, while peak data for the ocular rosacea program is expected in the first half of 2027.
-
The base case for the Lyme disease program involves delivering robust Phase II data before there is the ability to transition assets to a partner for larger Phase III trials.
Financial and Operational Context
-
Q1 results included a milestone one-time $15 million regulatory settlement from partner Grand Pharma following the approval of TPO3 in Greater China.
-
First-quarter performance was impacted by typical seasonal fluctuations, including drag resets and severe winter weather in the Northeast US.
-
The total is expected to remain stable at around 93% for the full year of 2026.
-
Management noted that while China’s earnings are expected to be long-term, they will not be meaningful until 2026 or 2027 as the partner works to secure the payer’s solvency.
Highlights of the Q&A Session
Competitive landscape and potential problems of tolerance of competing goods
Our analysts recently identified a stock that has the potential to be the next Nvidia. Tell us how you invest and we’ll show you why it’s our #1 choice. Tap here.
-
Management expressed confidence in XTENVI’s established safety and performance profile as the standard of care.
-
They noted that while other companies are entering the space, XTENVI’s strong evidence base and physician response puts it firmly against emerging clinical-stage products.
Speculation driving the high sales goal of $2 billion
-
A high level of sales assumes a steady state cancellation rate of approximately 20% of total orders.
-
Growth is also predicted from expanding the adjustable market through new use cases, such as preoperative cataract screening and treatment of chalazion-related conditions.
Key priorities and strengths of the Lyme Disease program
-
The company is focused on achieving Phase III readiness with the current 700-participant Phase II trial.
-
Management indicated that while they are developing the program independently now, the asset may be better suited for a larger partner to implement Phase III requirements such as immunizations.
Gross-to-net (GTN) power and regression effect
-
Management expects to exit the year with a GTN of between 43% to 45%.
-
They clarified that deferral orders do not significantly change the net cost recovery, as these patients still need prior authorization and copay support.
One stock. Nvidia-grade power. 30M+ investors hope Moby gets it first. Get a choice. Tap here.
